Janone Inc. (NASDAQ:ALTS - Get Free Report) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 62,900 shares, a decline of 50.4% from the December 15th total of 126,700 shares. Based on an average trading volume of 198,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.5% of the company's stock are short sold.
Janone Stock Performance
Shares of NASDAQ ALTS traded up $0.44 during mid-day trading on Tuesday, reaching $6.13. 224,603 shares of the company traded hands, compared to its average volume of 323,525. The company's fifty day moving average is $3.54. The company has a debt-to-equity ratio of 1.96, a quick ratio of 0.75 and a current ratio of 0.75. Janone has a fifty-two week low of $0.50 and a fifty-two week high of $7.09.
About Janone
(
Get Free Report)
JanOne Inc, a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology.
Read More
Before you consider Janone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janone wasn't on the list.
While Janone currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
